articleThe Lancet Diabetes & EndocrinologyFeb 5, 2024Closed access

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

CWCarel W. le RouxOSOren SteenKJKathryn Jean LucasESElena StartsevaAUAnna Unseld

University College Dublin · LMC Diabetes & Endocrinology (Canada) · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

178
total citations
FWCI
55.38
Percentile
100%
References
29
Citations per year

Authors

6

Topics & keywords

Topics
Keywords
  • Medicine
  • Placebo
  • Agonist
  • Glucagon-like peptide 1 receptor
  • Liraglutide
  • Glucagon-like peptide-1
  • Double blind
  • Internal medicine
No related works found for this paper.

Funding